Jinwon Life Sciences Subsidiary VGXI Completes Establishment of Personalized Neoantigen Cancer Vaccine Rapid Production System

[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 21st that its subsidiary VGXI successfully completed the establishment of a rapid production system by finishing cGMP production of a DNA-based personalized neoantigen cancer vaccine product within 5 days, conducting quality evaluation within 2 weeks, launching the product, and performing the patient's first dose.

A company official stated, “This product is a vaccine developed by the U.S. company Geneos Therapeutics that designs personalized neoantigens using the tumor genetic information of cancer patients and treats cancer in the form of a DNA vaccine. The goal is to complete from tumor tissue collection to cGMP production and patient administration within 6 to 8 weeks. The key to the successful development of this product was reducing the cGMP production and launch period of DNA vaccines, which typically takes 6 to 8 months on average, to within a few weeks. This was possible thanks to VGXI’s outstanding high-purity production technology.”

Park Young-geun, CEO of GeneOne Life Science, said, “Our subsidiary VGXI has successfully supported the core process of product development for our client with decades of accumulated experience and technology. This achievement is the production of the first product for Geneos Therapeutics’ personalized neoantigen cancer vaccine clinical study, and we will produce and supply rapid and high-quality products in line with the enrollment of clinical trial subjects.”

He added, “By providing services utilizing the rapid production system established this time, we expect to meet the production demands of companies developing personalized cancer vaccines, which are actively researched worldwide recently, thereby increasing sales and improving profitability.”

Dr. Niranjan Sardesai, CEO of Geneos Therapeutics, emphasized, “Rapidly completing the period from tumor tissue collection to production and administration is a major milestone enabling personalized treatment for patients with advanced cancer. We are very pleased that VGXI is the production partner for the clinical development of the Geneos GT-30 product. In particular, VGXI’s proven technology has resolved issues and achieved rapid cGMP production of our product.”

VGXI is responsible for the cGMP production of the clinical product of Geneos Therapeutics’ GT-30, a vaccine for advanced liver cancer.

Personalized neoantigen cancer vaccines involve extracting an individual’s cancer tissue, identifying cancer antigens specific to the individual, and administering genes expressing these antigens into the body to induce a personalized anti-cancer immune response. These vaccines are being developed in viral vector and plasmid forms.

Because they use cancer antigens derived from the individual, these vaccines have much higher therapeutic efficacy and no side effects compared to conventional general immuno-oncology drugs, attracting attention from multinational pharmaceutical companies as a future cancer immunotherapy.

This content was produced with the assistance of AI translation services.